About: Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $8.25 (-1.79%)
RNA NASDAQ Atrium Therapeutics, Inc. Common Stock
Atrium Therapeutics, Inc. Common Stock share price
Atividade de preço de RNA
Último preço
$ 8,260
Variação (24h)
-0,14 USD (1,67%)
Volume
155.78K
Volume (média 4 sem.)
-
Abertura
$ 8,52
Variação do dia
$ 8,20 - $ 8,65
Fechamento anterior
$ 8,40
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
RNA price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals